PMID- 33980810
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 11
IP  - 5
DP  - 2021 May 12
TI  - Measurable residual disease status and outcome of transplant in acute myeloid 
      leukemia in second complete remission: a study by the acute leukemia working 
      party of the EBMT.
PG  - 88
LID - 10.1038/s41408-021-00479-3 [doi]
LID - 88
AB  - Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) 
      for acute myeloid leukemia (AML) in first complete morphological remission (CR1) 
      is an independent predictor of outcome, but few studies address CR2. This 
      analysis by the Acute Leukemia Working Party of the European Society for Blood 
      and Marrow Transplantation registry assessed HCT outcomes by declared MRD status 
      in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were 
      transplanted 2006-2016 from human leukocyte antigen (HLA) matched siblings 
      (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was 
      myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had 
      in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) 
      and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer 
      in MRD NEG than MRD POS patients (18 vs. 16 months (P < 0.001). Two-year relapse 
      rates were 24% (95% CI, 21-28) and 40% (95% CI, 34-46) in MRD NEG and MRD POS 
      groups (P < 0.001), respectively. Leukemia-free survival (LFS) was 57% (53-61) 
      and 46% (40-52%), respectively (P = 0.001), but there was no difference in terms 
      of overall survival. Prognostic factors for relapse and LFS were MRD NEG status, 
      good risk cytogenetics, and longer time from diagnosis to HCT. In-vivo T cell 
      depletion predicted relapse.
FAU - Gilleece, Maria H
AU  - Gilleece MH
AUID- ORCID: 0000-0003-0364-3573
AD  - Leeds Teaching Hospitals Trust, St James's University Hospital, Leeds, LS9 7TF, 
      United Kingdom. mgilleece@nhs.net.
FAU - Shimoni, Avichai
AU  - Shimoni A
AUID- ORCID: 0000-0001-8782-6160
AD  - Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, 
      Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, 
      Israel.
FAU - Labopin, Myriam
AU  - Labopin M
AD  - EBMT Paris study office/CEREST-TC, Paris, France.
FAU - Robinson, Stephen
AU  - Robinson S
AD  - University Hospital Bristol NHS Foundation Trust, London, United Kingdom.
FAU - Beelen, Dietrich
AU  - Beelen D
AD  - Department of Bone Marrow Transplantation, West German Cancer Center, University 
      Hospital of Essen, Essen, Germany.
FAU - Socie, Gerard
AU  - Socie G
AD  - Hematologie/Transplantation, Hopital St Louis, Paris, CEDEX 10, France.
FAU - Unal, Ali
AU  - Unal A
AD  - Kapadokya BMT Center, Kayseri, Turkey.
FAU - Ganser, Arnold
AU  - Ganser A
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, 
      Hannover Medical School, Hannover, Germany.
FAU - Vitek, Antonin
AU  - Vitek A
AD  - Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech 
      Republic.
FAU - Sengeloev, Henrik
AU  - Sengeloev H
AD  - Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
FAU - Yakoub-Agha, Ibrahim
AU  - Yakoub-Agha I
AUID- ORCID: 0000-0003-4524-8782
AD  - CHU de Lille, LIRIC, INSER U995, Universite de Lille, Lille, France.
FAU - Tholouli, Eleni
AU  - Tholouli E
AD  - Manchester Royal Infirmary, Manchester, United Kingdom.
FAU - Polge, Emmanuelle
AU  - Polge E
AD  - Acute Leukemia Working Party, European Society for Blood and Marrow 
      Transplantation Paris Study Office/European Center for Biostatistical and 
      Epidemiological Evaluation in Hematopoietic Cell Therapy (CEREST-TC), Paris, 
      France.
FAU - Mohty, Mohamad
AU  - Mohty M
AUID- ORCID: 0000-0002-7264-808X
AD  - Hopital Saint Antoine, INSERM UMR 938, Paris, France; Universite Pierre et Marie 
      Curie, Paris, France.
FAU - Nagler, Arnon
AU  - Nagler A
AD  - Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210512
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*diagnosis/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual/*diagnosis
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC8116335
COIS- The authors declare no competing interests.
EDAT- 2021/05/14 06:00
MHDA- 2022/01/11 06:00
PMCR- 2021/05/12
CRDT- 2021/05/13 05:47
PHST- 2020/05/31 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2020/11/07 00:00 [revised]
PHST- 2021/05/13 05:47 [entrez]
PHST- 2021/05/14 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/05/12 00:00 [pmc-release]
AID - 10.1038/s41408-021-00479-3 [pii]
AID - 479 [pii]
AID - 10.1038/s41408-021-00479-3 [doi]
PST - epublish
SO  - Blood Cancer J. 2021 May 12;11(5):88. doi: 10.1038/s41408-021-00479-3.